Making new medicines for people with serious diseases

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

A video about Regeneron's corporate mission.

Watch what drives us

Regeneron by the numbers


years of scientific leadership


employees worldwide across 12 countries


medicines approved in the U.S. and/or other countries


product candidates in clinical development across multiple therapeutic areas


countries with Regeneron clinical trials


global and U.S. patient advocacy and professional societies engaged across 40+ diseases

Top 10%

ranking in biotech industry across 3 leading environmental, social and governance (ESG) ratings

Find Regeneron around the globe

Technology for now and the future

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. 

We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

How we turn science into medicine

Two people working in a lab together.

Doing well by doing good

Through responsible business practices and with the highest standards of integrity, we rise to any challenge with our characteristic drive and science-led approach. Our 2025 responsibility goals support the United Nations Sustainable Development Goals (SDGs) and span our three strategic focus areas:

A woman working with a beaker in a lab.

Improving the lives of people
with serious diseases

Two employees collaborating at a table.

Fostering a culture of
integrity and excellence

Three people looking at a camera and smiling during the Regeneron Day for Doing Good.

Building sustainable

We are proud of the rankings and recognitions we have received for our corporate responsibility leadership and efforts.
  • S&P Global: Top 1% in the biotechnology industry; Member: Dow Jones Sustainability Index World and North America, 2023
  • Sustainalytics: Top 2% in biotechnology industry
  • MSCI: A (ESG Rating, as of April 2023)
  • FTSE4Good: 3.9 score; Member: FTSE4Good Index Series
  • ISS-ESG: B-, (ESG Corporate Rating)
  • Eight consecutive years on Civic 50 list of the most community-minded companies in the U.S.
  • Best Community Partnership with Society for Science by Scrip for Regeneron Science Talent Search
  • Newsweek: America’s Most Responsible Companies, 2023
  • Biospace: Best Place to Work, 2023
  • Glassdoor: Best Places to Work, 2023
  • Newsweek: America’s Greatest Workplaces for Diversity, 2023 
  • Science: Top Employer, 2023

Learn about our culture and workplace

to top